Sat, Apr 19, 2014, 8:58 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

reyeton1 10 posts  |  Last Activity: Mar 21, 2014 9:25 AM Member since: Apr 5, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Answer

    by yuzzvln Jan 24, 2014 3:42 PM
    reyeton1 reyeton1 Jan 25, 2014 12:09 AM Flag

    I don't consider myself a 'moron' but if anything illegal and I'll add, unethical, has or is happening behind the scenes, I hope the guilty party, whoever that is, finds their #$%$ in jail, the same place I would end up for similar activities. The lack of transparency doesn't bode well for CT. She needs to say something to us shareholders, NOW.

  • Reply to

    CCROCCA

    by yuzzvln Jan 31, 2014 4:35 PM
    reyeton1 reyeton1 Feb 5, 2014 1:20 PM Flag

    She did appoint a new CEO. The man that heads the Israeli company we are in talks to merge with.

  • Announced 12/4/13
    Therapix Biosciences Ltd.
    Merger/Acquisition
    Viropro Inc. (OTCPK:VPRO) signed a non-binding letter of intent to acquire Therapix Biosciences Ltd. (TASE:TRPX) from a group of investors on December 4, 2013. The investors are The Pontifax Fund, fund of Pontifax Ltd., IBI Mutual Funds Management Ltd., Gilbood Trading S.A, Quantum Technology Management Company IV, LLC and other shareholders.

    The Pontifax Fund specilizes start-ups. The fund seeks to invest in pharmaceutical and life sciences companies with a focus on medical devices companies based in Israel. It seeks board representation in its portfolio companies. Mr. Ran Nussbaum is a Co-Founder, Managing Partner, and Partner at The Pontifax Group and Pontifax Ltd. Mr. Nussbaum served as the Chief Executive Officer of Biomedix. He was a Partner and General Manager of Israel's largest business intelligence company. His real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. He serves as the Chairman of OCON Medical Ltd. He served as the Chairman of NasVax Ltd. He serves as Vice Chairman of Biomedix (BMDX). He serves as Co-Director of The Pontifax Fund. He serves as a Director of TheraCoat Ltd., Kite Pharma, Inc., Meytav Technological Incubato, cCAM Biotherapeutics Ltd, Collplant, Protab, AIT, Fusimab Ltd ,and Omer Therapeutics Ltd.


    IBI Mutual Fund Management Ltd., established in 1978, is one of the oldest and top fund firms in the mutual fund industry in Israel.  
     
    The company manages 42 mutual funds with a net asset value of approximately NIS 13 billion.*
    Our mutual funds provide a highly stable and superior quality platform for capital management in all investment areas in Israel and in key investment areas overseas.
     
    IBI's mutual funds are unique in that they reflect not only our determination to achieve superior returns but also a consistency in investment style and policy over the long term.
     
    Investment Philosophy
     
    Our investment philosophy is, accordingly, based, first and foremost, on quality and integrity. We firmly believe that, one cannot create the quality content needed to deliver added value in each fund without in-depth knowledge, hands-on experience and the right technical parameters. 
    This defining infrastructure is central to the multi-tiered process that constitutes a key component in our fund management. This process is broken down as follows:
     
    Tier one – Intelligent use of various instruments in the fixed income market aimed at achieving a superior return to risk-free interest rates.
    Tier two – Leveraging financial market anomalies at both the micro- and the macro-economic levels.
    Tier three – Reliance on up-to-the-minute research and in-depth knowledge to identify the equities and bonds of investment-grade companies.
     
    We stress that along with our "Buy and Hold" style investments in growth companies and value investments, there are also instances where we make short-term investments in accordance with milestones in company development or market conditions.
     
    Our investment philosophy combines a dynamic approach to markets with a long-term economic perspective.  Markets have been exceptionally volatile post the “once in 80 years crisis,” and this volatility should not, in our opinion, be a deterrent – quite the contrary. While volatility can cause a great many difficulties, it is also the source of innumerable opportunities to locate economic value in the equity and bond markets on an absolute rather than a proportionate basis. It is precisely these opportunities that we aim for, and we make intelligent use of them in our day-to-day management in each of IBI's mutual funds .

    Gilbood Trading S.A: No information

    Quantum Technology Management Company IV: No information

  • Reply to

    Did viropro filed their response to the suit?

    by goodinvestor99 Feb 10, 2014 10:16 AM
    reyeton1 reyeton1 Feb 10, 2014 4:56 PM Flag

    I didn't hear the fat lady sing.

  • reyeton1 by reyeton1 Feb 14, 2014 12:25 PM Flag

    2,700,000 on the buy side

  • Reply to

    SELL NOW BEFORE MORE BROKERS PUT PRPM ON DTC CHILL

    by tommer1969 Feb 15, 2014 11:32 PM
    reyeton1 reyeton1 Feb 16, 2014 7:19 AM Flag

    I clicked on your name to see what you've been up to. Seems like you're chilling all over the place. I had no trouble buying shares and by the volume that is being traded, seems like not many others are either. Chill out dude.

  • Reply to

    PRPM is going up

    by rstuprx7 Feb 18, 2014 8:51 PM
    reyeton1 reyeton1 Feb 18, 2014 10:23 PM Flag

    so if there's no "news" tomorrow...... does that mean it closes down ONE tick

  • http://www.cnbc.com/id/101411848

  • Reply to

    warning

    by ke_moe Mar 11, 2014 11:03 AM
    reyeton1 reyeton1 Mar 12, 2014 9:44 AM Flag

    Louis Porter / Chairman, Bayport Corporation

    Mr. Louis Porter of Tulsa, Oklahoma is CEO and Board Chairman of Bayport Corp. He received a B.S in Petroleum and Natural Gas Engineering from Texas A&I in Kingsville, Texas 1970, now affiliated with Texas A&M. He was a member of the Sigma Tau and Alpha Chi honor societies – Sigma Tau Honor Engineer Alpha Chi Honor Scholastic. He worked five years with Arco as a Petroleum Engineer, Drilling, Gasoline Plant, Reservoir Engineering and Sales of LPG’s. Then Mr. Porter spent 5 years with Thermogas as its Transportation Director, as well as Operations Manager for purchasing wholesale and the retail selling of propane and butane for the entire network. Thermogas was the largest LPG distributor of LPG’S in the nation at that time until merged with Mid America Pipeline.

    He started NGL Supply (Natural Gas Liquids) which later became Dalco Petroleum a Public Company in the United States and was 87% owner of Dynex Petroleum a Public Company across Canada and headquartered in Calgary Alberta. He was CEO & Major Owner of 87% of stock in the Canadian operation & CEO and President with 90% stock in Dynex USA. Dynex was very strong in Canada with sales reaching approximately 1 Billion dollars Canadian in oil and gas. Dynex successfully engineered a $75 Million revolving line of credit with Bank of Montreal.

    Thanks for the warning. Seems like you're having a bad dream. This stock isn't for weaklings. Maybe you should buy a CD or a savings bond. Good luck!

  • Reply to

    Any hope left?

    by suchahotsummer Mar 17, 2014 1:47 PM
    reyeton1 reyeton1 Mar 21, 2014 9:25 AM Flag

    The only hope is that the guilty will spend a significant time in jail. I got out at .01. If it goes to .0001, I may jump in and buy 10,000,000 shares. It's tough letting go.

BIIB
290.54-0.94(-0.32%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.